COUR Pharmaceuticals is a clinical-stage biotechnology company headquartered in Evanston, Illinois, founded in 2015. The firm focuses on reprogramming the immune system to develop novel treatments for autoimmune diseases.
Subscribe to see Cour’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Cour is a drug discovery company headquartered in Evanston, United States. It has raised at least $155M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $50M in June 2026. Xcout tracks 17 named people at Cour, including Dannielle Appelhans (President and CEO).
As of 16 November 2026. Source: Xcout Intel.
11 more named people on record for Cour, with roles, board committees and tenure — see the full roster →
At least $155M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $50M | 8 named | |
| Series A | $105M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A funding-flow diagram of the 8 named investors across 2 rounds: who backed which round, who led it, and who came back for the next one.
Sign in to see it, or subscribe for the full funding history →
A few of Cour's closest competitors — see the full list of competitors and alternatives →
Coultreon Biopharma is a clinical-stage biotechnology company headquartered in Leuven, Belgium, focused on developing next-generation precision medicines for immunology and autoimmune diseases. Backed by substantial venture funding, the company advances innovative therapies.
NXI Therapeutics AG is a biotech company based in Basel, Switzerland, focused on researching and developing selective immunosuppressive drugs and immunotherapies for autoimmune diseases and transplantation.
Syntax Bio is a biotechnology research company headquartered in Chicago, Illinois, focused on synthetic biology. The company utilizes its proprietary Cellgorithm CRISPR-based platform to program stem cells and accelerate the development of next-generation organoids and cell-derived therapies.
Promise Bio is a biotechnology research startup transforming immune-mediated disease treatment with advanced precision therapies. Headquartered in Tel Aviv, Israel, the company emerged from stealth following a seed investment.
Promontory Therapeutics Inc. is a privately held, clinical-stage pharmaceutical company founded in 2010 and headquartered in New York, NY. The firm focuses on small molecule immunotherapy.
AllIn Bio is a drug discovery company headquartered in Woodside, California. The firm is developing a precision-immunology approach designed to treat the root cause of chronic inflammatory diseases.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Cour? Suggest a correction · Work at Cour? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.